NKG2D CAR T cell therapy - UWELL Biopharma
Alternative Names: NKG2D CAR T cell therapyLatest Information Update: 03 Feb 2021
At a glance
- Originator UWELL Biopharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 01 Feb 2021 Preclinical trials in Glioblastoma in Taiwan (Intracerebral) prior to February 2021
- 01 Feb 2021 UWELL Biopharma plans a clinical trial in Glioblastoma (Recurrent, Second-line therapy or greater) in Taiwan (Intracerebroventricular, Injection) in September 2021 (NCT04717999)